Form 4: Kura Oncology Legal Officer Sells Shares for Tax Cover

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, sold common stock on January 27, 2026, to cover tax obligations related to vested restricted stock units.

Summary

• Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, Inc., reported transactions involving the company's common stock.
• On January 27, 2026, Ms. Bair disposed of a total of 11,208 shares of Kura Oncology common stock across three separate transactions.
• The shares were sold at a price of $8.4607 per share.
• These sales were conducted as "sell-to-cover" transactions to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
• The RSUs were received on January 2, 2025, February 16, 2023, and January 2, 2024.
• Following these transactions, Ms. Bair beneficially owns 226,931 shares of Kura Oncology common stock directly.
• The transactions were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sell-to-cover for taxes) which is a neutral event and does not reflect positively or negatively on the company's operational or financial performance.

Positives

• The transactions represent the vesting of restricted stock units (RSUs), indicating compensation for the Chief Legal Officer.

Negatives

• No specific negative implications are apparent from a routine sell-to-cover transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly 'sell-to-cover' sales for tax obligations upon RSU vesting, are a common and routine occurrence in publicly traded companies. These transactions are generally not indicative of management's sentiment towards the company's future prospects but rather a standard compensation and tax management practice for executives.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard industry practice for executives to manage tax liabilities associated with the vesting of equity awards like Restricted Stock Units (RSUs).
• The use of a Rule 10b5-1 plan aligns with best practices in corporate governance, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary sale indicating a lack of confidence.
• Employees: No direct impact, but reflects standard executive compensation practices.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Sell-to-Cover, Teresa Brophy Bair, Corporate Officer